Xilio Therapeutics (XLO) Net Shares Issued and Repurchased (2020 - 2026)

Xilio Therapeutics has disclosed Net Shares Issued and Repurchased across 7 years of filings, most recently posting $26988.0 for Q1 2026.

• In Q1 2026, Net Shares Issued and Repurchased fell 99.05% year-over-year to $26988.0; the TTM figure through Mar 2026 stood at $26988.0 (down 99.05% YoY), while the FY2025 annual figure was $2.6 million, down 0.63% from the prior year.
• Net Shares Issued and Repurchased came in at $26988.0 for Q1 2026 at Xilio Therapeutics, down from $2.6 million in the prior quarter.
• In the past five years, Net Shares Issued and Repurchased ranged from a high of $3.7 million in Q4 2023 to a low of $26988.0 in Q1 2026.
• Average Net Shares Issued and Repurchased over 5 years is $1.8 million, with a median of $1.7 million recorded in 2022.
• Year-over-year, Net Shares Issued and Repurchased surged 354.99% in 2025 and slumped 99.05% in 2026.
• Over 5 years, Net Shares Issued and Repurchased stood at $1.7 million in 2022, then surged by 114.2% to $3.7 million in 2023, then tumbled by 30.95% to $2.6 million in 2024, then decreased by 0.63% to $2.6 million in 2025, then slumped by 98.95% to $26988.0 in 2026.
• Per Business Quant data, the three most recent Net Shares Issued and Repurchased figures were $26988.0 in Q1 2026, $2.6 million in Q4 2025, and $2.9 million in Q1 2025.